Skip to Content

Join the 'Renal Cell Carcinoma' group to help and get support from people like you.

Renal Cell Carcinoma News

Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer

Freeze Therapy: An Alternative to Breast Cancer Surgery?

Posted 17 days ago by

TUESDAY, Oct. 11, 2016 – A freezing technique known as cryoablation might be a viable alternative to lumpectomy for treating small, early stage breast cancers, researchers report. In the small study of 86 patients, "cryoablation was shown to successfully [treat] the majority of small breast cancers with few side effects or complications," said study co-author Dr. Deanna Attai. She's an assistant clinical professor of surgery at the University of California, Los Angeles David Geffen School of Medicine. Using this minimally invasive approach to destroy cancer cells, there should be little to no change in the appearance of the breast, said Attai, immediate past president of the American Society of Breast Surgeons. The major risk, Attai said, is not killing all the cancerous cells. Another surgeon noted that although further research is still needed, cryoablation appears to be "a potential ... Read more

Related support groups: Cancer, Breast Cancer, Lung Cancer, Renal Cell Carcinoma, Breast Cancer - Adjuvant, Breast Cancer, Prevention

Do Overweight People Fare Better Than Others With Kidney Cancer?

Posted 7 Sep 2016 by

WEDNESDAY, Sept. 7, 2016 – Obesity is a risk factor for kidney cancer. Yet, obese people with advanced kidney cancer seem to live longer than normal-weight or underweight patients, a new study finds. In one database of nearly 2,000 patients with advanced kidney cancer, those who were obese or overweight survived nearly 26 months, compared to 17 months for those of normal weight. And, overweight patients were 16 percent less likely to die during the study period, the researchers reported. Similar findings were uncovered using three other databases. The records of more than 7,000 kidney cancer patients were reviewed by the study authors. "Paradoxically, when overweight individuals developed kidney cancer, especially in its advanced, metastatic form, their disease progressed more slowly and they lived longer than their normal-weight counterparts," said lead researcher Dr. Toni Choueiri. ... Read more

Related support groups: Obesity, Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Urinary Tract Tumors, Wilms' Tumor, Urinary Tract Cancer

Excess Weight Tied to Higher Risk for Many Cancers, Experts Say

Posted 25 Aug 2016 by

WEDNESDAY, Aug. 23, 2016 – Staying slim throughout your life might lower your risk of developing at least eight types of cancer, an international cancer research group says. Those include cancers of the stomach, liver, gallbladder, pancreas, ovary and thyroid. The list also includes a form of brain cancer known as meningioma, as well as a type of blood cancer called multiple myeloma. What's more, the latest research builds on the findings of an earlier review by the International Agency for Research on Cancer (IARC), which is part of the World Health Organization. That research found that those who avoid gaining weight can curtail their risk for developing five other types of cancer, including cancer of the colon, esophagus, kidney, breast and uterus. "The review certainly concluded crystal clear, as you say, that obesity causes cancer," noted Dr. Graham Colditz, who chaired the IARC ... Read more

Related support groups: Obesity, Cancer, Breast Cancer, Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Cancer, Urinary Tract Cancer

FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

Posted 16 May 2016 by

WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ – Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy. This approval was based on the impressive results of the registration study (Study 205), in which the once daily combination of 18 mg Lenvima and 5 mg everolimus demonstrated a substantial improvement in progression-free survival (PFS), powerful objective response rate (ORR) and clinically meaningful overall survival (OS) when compared with everolimus alone, a standard of care for patients with aRCC who have received prior anti-angiogenic therapy. "Lenvatinib plus everolimus is the first and only FDA-approved ... Read more

Related support groups: Renal Cell Carcinoma, Lenvima, Lenvatinib

Could Talk Therapy Ease Chemo-Related Memory Issues?

Posted 2 May 2016 by

MONDAY, May 2, 2016 – A type of psychotherapy might help cancer survivors deal with the long-term thinking problems some experience after chemotherapy, researchers say. It's estimated that about half of those who undergo chemotherapy for cancer develop what's often called "chemo brain." For instance, they may have trouble following conversations or remembering the steps in a project, according to background notes with the new study. Although usually mild, these changes can affect quality of life, job performance and relationships, said the researchers from the Eastern Maine Medical Center and Lafayette Family Cancer Center in Bangor, Maine. The researchers developed a cognitive-behavioral therapy (CBT) program called Memory and Attention Adaptation Training to help cancer survivors prevent or manage these memory problems. Their study involved 47 breast cancer survivors who underwent ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Prostate Cancer, Fluorouracil, Lung Cancer, Gleevec, Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, Metastatic, Non-Small Cell Lung Cancer, Brain Tumor, Melanoma, Xeloda, Pancreatic Cancer, Skin Cancer, Tasigna, Ovarian Cancer, Sprycel, Herceptin

Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma

Posted 27 Apr 2016 by

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. Cabometyx, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters — overall survival, progression-free survival and objective response rate. “With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer w ... Read more

Related support groups: Renal Cell Carcinoma, Cabometyx, Cabozantinib

Drug Seems to Extend Survival for Advanced Melanoma Patients

Posted 18 Apr 2016 by

MONDAY, April 18, 2016 – More than one-third of advanced melanoma patients were still alive five years after starting therapy with the cancer drug nivolumab (Opdivo), researchers are reporting. "In 2012, we saw some very promising early evidence that this drug could not only cause the regression of very advanced cancer in patients with melanoma, lung or kidney cancers that had not responded to other forms of therapy, but we also saw that these responses appeared to be very durable," said lead researcher Dr. Suzanne Topalian. She is a professor of surgery and oncology at Johns Hopkins University School of Medicine, in Baltimore. Opdivo was approved for the treatment of advanced melanoma by the U.S. Food and Drug Administration in 2014. The results of this follow-up study, funded by Bristol-Myers Squibb, which makes Opdivo, were to be presented Sunday at the American Association for ... Read more

Related support groups: Lung Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Small Cell Lung Cancer, Melanoma - Metastatic, Opdivo, Nivolumab, Wilms' Tumor

Certain Biopsy Method Tied to Better Outcomes After Kidney Cancer

Posted 10 Mar 2016 by

THURSDAY, March 10, 2016 – A type of lab test called a "core-needle biopsy," performed on tissue taken from a mass on a kidney, may be better for certain kidney cancer patients, new research suggests. The study involved people with a renal (kidney) cell carcinoma – the most common type of kidney cancer in adults. Researchers led by Dr. Rosaleen Parsons, of Fox Chase Cancer Center in Philadelphia, noted that incidence and death rates of the disease have climbed in recent decades. But they added that so-called "image-guided" core-needle biopsy of kidney masses is increasingly being used to determine the best treatment approaches for individual patients. In their study, Parsons' team researchers tracked outcomes for patients who collectively underwent 374 kidney mass biopsies between 1999 and 2015. Core-needle biopsy – meaning that a tiny amount of tissue is removed using a hollow ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Diagnosis and Investigation

Is Type 1 Diabetes Linked to Raised Risk of Certain Cancers?

Posted 2 Mar 2016 by

TUESDAY, March 1, 2016 – Having type 1 diabetes may raise the risk of some cancers, but lower the risk of others, a new study suggests. A higher risk was seen for cancers of the stomach, liver, pancreas, endometrium, ovary and kidneys. But a reduced risk was seen for prostate and breast cancers, researchers reported. In type 1 diabetes, the body cannot produce the hormone insulin, which helps regulate blood sugar levels. People with type 1 diabetes must be treated with insulin to survive. The good news from this study, said researcher Sarah Wild, is that it doesn't seem that insulin treatment is responsible for an increased risk of some cancers, which has been a concern. "This pattern of cancer risk [seen in the study] is similar to that seen for people with type 2 diabetes and people who are overweight," said Wild, a professor of epidemiology at the University of Edinburgh in the ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Diabetes, Type 1, Renal Cell Carcinoma, Pancreatic Cancer, Ovarian Cancer, Diabetes Mellitus, Stomach Cancer, Wilms' Tumor

Targeted Drug Shows Promise Against Advanced Kidney Cancer

Posted 6 Jan 2016 by

WEDNESDAY, Jan. 6, 2016 – A targeted cancer drug appears to be effective against advanced kidney cancer, although its side effects may keep it from becoming widely used, researchers report. The drug, cabozantinib, proved more effective across-the-board in kidney cancer patients than another targeted drug called everolimus, said lead researcher Dr. Bernard Escudier. He is chair of the genitourinary oncology committee at the Institut Gustave Roussy in Villejuif, France. Overall, cabozantinib provided "almost a 50 percent improvement in progression-free survival" over everolimus, Escudier said. Cabozantinib works by interrupting several different cellular processes that help cancer grow and spread, Escudier explained. Unfortunately, that widespread approach also creates worrisome toxic side effects, he added. "Based on this multi-targeted action, we have quite a lot of side effects. ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Urinary Tract Tumors, Solid Tumors, Cometriq, Cabozantinib, Urinary Tract Cancer

FDA Approves Opdivo to Treat Metastatic Renal Cell Carcinoma

Posted 23 Nov 2015 by

November 23, 2015 – The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is one of few therapies that have demonstrated the ability to extend patients’ survival in treating this disease.” Torisel (temsirolimus), approved in 2007, is the only other FDA-approved therapy that has demonstrated overall survival in renal cell cancer. Renal cell carcinoma is the most common form of kidney cancer in adults and forms in the tissues of the kidney that make urine. The National Cancer Institute estimates 61,560 ... Read more

Related support groups: Renal Cell Carcinoma, Opdivo, Nivolumab

Barbecued, Pan-Fried Meat May Boost Kidney Cancer Risk

Posted 9 Nov 2015 by

MONDAY, Nov. 9, 2015 – Cooking meats at high temperatures, as in barbecuing or pan-frying, may increase the risk for kidney cancer, a new study suggests. The World Health Organization warned last month that processed meats – including bacon, hot dogs and sausages – can cause colon cancer. Red meats were also associated with higher risk. The new study looked specifically at kidney cancer, which is increasing in the United States and other developing nations. "This study, and others like it, suggest that the way we cook our meat could potentially impact kidney cancer risk," said lead researcher Dr. Xifeng Wu, a professor in the department of epidemiology at the University of Texas MD Anderson Cancer Center in Houston. "Limit the amount of time the meat is cooked at really high temperatures or over an open flame resulting in burning, smoking, or charring of the meat," Wu suggested. ... Read more

Related support groups: Renal Cell Carcinoma

New Immune-Focused Drug Shows Promise Against Advanced Kidney Cancer

Posted 25 Sep 2015 by

FRIDAY, Sept. 25, 2015 – A new drug that harnesses the power of the immune system to fight tumors appears to help people battling advanced kidney cancer, a new study finds. The drug, Opdivo (nivolumab), outperformed a standard chemotherapy, Afinitor (everolimus), in terms of shrinking tumors and boosting patient survival, the study found. The study was funded by Bristol-Myers Squibb, which makes Opdivo. It was to be presented Friday at the European Cancer Congress in Vienna, and is being published simultaneously in the New England Journal of Medicine. The new findings "are significant and clinically meaningful to patients and health care professionals alike," senior researcher Dr. Padmanee Sharma, of the University of Texas M.D. Anderson Cancer Center in Houston, said in a meeting news release. Sharma, a professor in the departments of genitourinary medical oncology and immunology, ... Read more

Related support groups: Renal Cell Carcinoma, Afinitor, Opdivo, Wilms' Tumor

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Prostate Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Femara, Fluorouracil, Lupron Depot, Lung Cancer, Gleevec, Colorectal Cancer, Renal Cell Carcinoma, Isotretinoin

Smoking Ups Risk of Complications From Urologic Cancers: Study

Posted 15 May 2015 by

FRIDAY, May 15, 2015 – Current and former smokers have more complications from major surgery for some urology-related cancers, according to new research. But even though former smokers have a higher risk of complications than non-smokers, the study also found that quitting smoking for as little as a year before surgery could "significantly" improve the outcomes of surgery. "These findings should provide motivation for all patients to quit smoking before undergoing major surgery. It's clear that they can expect better results with fewer complications if they do," Dr. Akshay Sood, a urologist and researcher at Henry Ford Hospital's Vattikuti Urology Institute, said in a hospital news release. The researchers focused on just over 9,000 patients who underwent surgery for cancers of the prostate, bladder or kidney from 2005 to 2011. They found that smokers were more likely to suffer from ... Read more

Related support groups: Smoking, Renal Cell Carcinoma, Bladder Cancer

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Wilms' Tumor, Cancer

Related Drug Support Groups

Provera, Depo-Provera, medroxyprogesterone, Votrient, Tarceva, Avastin, Sutent, Afinitor, Nexavar, view more... Opdivo, PegIntron, pazopanib, capecitabine, sunitinib, erlotinib, sorafenib, Depo-Provera Contraceptive, nivolumab, interferon alfa-2a, bevacizumab, Torisel, Lenvima, peginterferon alfa-2b, Inlyta, everolimus, Proleukin, Cabometyx, depo-subQ provera 104, Roferon-A, axitinib, temsirolimus, lenvatinib, aldesleukin, Amen, Curretab, cabozantinib, Cycrin